HSK0935
Modify Date: 2024-01-02 09:07:07
HSK0935 structure
|
Common Name | HSK0935 | ||
|---|---|---|---|---|
| CAS Number | 1638851-44-1 | Molecular Weight | 436.88 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C22H25ClO7 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of HSK0935HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities[1]. |
| Name | HSK0935 |
|---|
| Description | HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC50 of 1.3 nM. Antihyperglycemic activities[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 1.3 nM (SGLT2)[1] |
| In Vitro | HSK0935 (Compound 31) demonstrates excellent hSGLT2 inhibition of 1.3 nM and a high hSGLT1/hSGLT2 selectivity of 843-fold[1]. |
| In Vivo | HSK0935 treatment (1, 3, and 10 mg/kg) shows robust urinary glucose excretion in Sprague−Dawley (SD) rats and affects more urinary glucose excretion in Rhesus monkeys[1]. HSK0935 is well tolerated up to 300 mg/kg without any mortality or severe untoward effects in a 28-day repeat-dose toxicology study in beagle dogs[1]. |
| References |
| Molecular Formula | C22H25ClO7 |
|---|---|
| Molecular Weight | 436.88 |